IMALPHAX is the IMMANX division's combination prescription therapy addressing both erectile dysfunction and premature ejaculation through a single oral dose. The category exists because over 30% of men with ED report concurrent PE - yet most pharmacies stock two separate products and most distributors negotiate two separate supply lines.
Indications
mg formulation
Prescription
Available now
Each 5g sachet delivers a single combination dose: sildenafil 100mg and dapoxetine 60mg in a pharmaceutical-grade oral jelly. Distributor partners can specify tablet format in territories where pharmacy preferences require it.
Engineered Alpha.
Sildenafil 100mg + Dapoxetine 60mg
Sildenafil citrate 100mg addresses erectile dysfunction; dapoxetine HCl 60mg addresses premature ejaculation. Together in a single oral dose, supported by published combination-therapy literature.
Available as oral jelly (IMBOLDX-style sachet) or as a film-coated tablet, depending on territory pharmacy preferences and your distribution channels.
One prescription. One pharmacy interaction. One dose. The simplest patient pathway in the dual-indication category — translating directly to higher refill rates for distributor partners.
The sildenafil + dapoxetine combination is supported by published evidence for the dual indication of erectile dysfunction with concurrent premature ejaculation — a condition affecting more than 30% of men with ED according to global epidemiology data.
Dapoxetine 60mg improves intravaginal ejaculatory latency time by approximately three-fold versus placebo in pivotal trials.
McMahon et al, 2010
Sildenafil 100mg in the higher-dose arm consistently reports the highest IIEF erectile function score improvement in PDE5-inhibitor trials.
Goldstein et al, NEJM 1998
Over 30% of men presenting with erectile dysfunction also report premature ejaculation — the commercial case for combination therapy.
Laumann et al, 2005
IMALPHAX inherits the IMMANX division's complete manufacturing and regulatory infrastructure — same FDA-registered facility, same documentation standard, same traceability.
Same accredited facility that produces IMBOLDX and the rest of the IMMANX portfolio. Cross-product validation already in place.
Active ingredients managed under International Council for Harmonisation guidelines. Master file shared across distributor submissions.
HPLC assay verification on every production batch. Documented dose accuracy on the certificate of analysis.
Track-and-trace barcodes on every outer carton. Distributors and regulators can verify lineage end-to-end.
Distributor partnerships for IMALPHAX are open under signed IMMANX agreements. Reach out for product specifications, sampling, territory reservations, and pricing structures.
Engineered Alpha.
An IMMANX brand
Pharmaceutical and nutraceutical R&D, USA cGMP manufacturing, and global B2B distribution. IMMANX is the men's health division of QuadroPharma.
QuadroPharma Inc
280 Moon Clinton Rd
Moon Township
PA 15108, USA
QuadroPharma FZ LLC
Unit 452, Level 3, The Offices 3
One Central, DWTC
Sheikh Zayed Road
Dubai, UAE